Lv2
134 积分 2022-02-28 加入
Sacituzumab Tirumotecan in EGFR-TKI–Resistant, EGFR -Mutated Advanced NSCLC
16小时前
待确认
SYS6010, epidermal growth factor receptor-targeting antibody-drug conjugate for advanced non-small cell lung cancer: A phase 1 trial
18小时前
已完结
Ruzaltatug rezetecan versus chemotherapy for EGFR-mutated advanced non-small-cell lung cancer progressing after EGFR tyrosine kinase inhibitor therapy (HERON-Lung01): interim analysis of a randomised, open-label, phase 3 trial in China
19小时前
已完结
Doublet chemotherapy, triplet chemotherapy, or doublet chemotherapy combined with radiotherapy as neoadjuvant treatment for locally advanced oesophageal cancer (JCOG1109 NExT): a randomised, controlled, open-label, phase 3 trial
23天前
已完结
Prognostic Significance and Biomarker Identification by Progression Patterns in Patients With Small Cell Lung Cancer After Immune Checkpoint Inhibitors
1个月前
已完结
Immunotherapy rechallenge in extensive-stage small-cell lung cancer: A real-world retrospective study
1个月前
已完结
Platelet–lymphocyte ratio is a prognostic marker in small cell lung cancer—A systemic review and meta-analysis
1个月前
已完结
Sacituzumab Tirumotecan in EGFR-TKI–Resistant, EGFR -Mutated Advanced NSCLC
2个月前
已完结
Datopotamab deruxtecan versus chemotherapy in previously treated inoperable/metastatic hormone receptor-positive, HER2-negative breast cancer: final overall survival analysis of the phase III TROPION-Breast01 study
4个月前
已完结
Sacituzumab Tirumotecan in EGFR-TKI–Resistant, EGFR -Mutated Advanced NSCLC
6个月前
已完结
皖公网安备34019202002308
